Lilly invests over 3.5 billion US dollars to build a factory and produce GIPR/GLP-1R/GCGR three target weight loss drugs
On January 30, 2026, Eli Lilly and Company announced that it will invest over $3.5 billion to build a new injection drug and device production base in Pennsylvania, focusing on the production of next-generation weight loss therapies, including the first ongoing GIPR/GLP-1R/GCGR triple target agonist, retatrutide.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Injection
(4)Capsules
(5)Cream
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: KP-2-3/003
Retatrutide CAS 2381089-83-2
HS code: N/A
EINECS: 200-001-8
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
We provide retatrutide, please refer to the following website for detailed specifications and product information.
Product: https://www.kpeptide.com/bodybuilding-peptide/retatrutide-injection-10-mg.html
This is the fourth new production base in the United States announced by Eli Lilly since February 2025, and also the 10th production base it has laid out since 2020. In terms of production capacity and employment, the base is expected to start construction in 2026 and officially put into operation in 2031. It will directly create 850 jobs, including engineers, researchers, laboratory technicians, etc. During the construction period, it will also generate 2000 construction jobs, driving a total of over 2800 job opportunities.
In terms of technological application, the base will introduce cutting-edge technologies such as artificial intelligence and machine learning to ensure efficient production and stable drug supply. In addition, Lilly will also cooperate with local universities to increase investment in education in Pennsylvania, assist in the cultivation of local professional talents, and deepen its connection with the regional industrial ecology.
First approved for the world's first biased GLP-1 enoglutide injection
On January 30, 2026, Hangzhou Xianweida Biotechnology Co., Ltd. (hereinafter referred to as "Xianweida Biotechnology"), a biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, announced: Xianyida ® (Enoglutide injection) was approved by the National Drug Administration (NMPA) for blood glucose control in adult patients with type 2 diabetes, and became the first cAMP biased GLP-1 approved for marketing in the world receptor agonists. Enoglutide injection is the first cAMP biased GLP-1 receptor agonist approved for marketing in the world. Different from the non biased GLP-1 receptor agonist, enoglutide selectively activates the cAMP signal pathway while minimizing the collection of B-arrestin. This signal bias limits the desensitization and down-regulation of receptors, leaving more receptors on the cell surface and maintaining therapeutic signal transduction.
The unique mechanism of the biased type is one of the key factors for its improvement of clinical efficacy and metabolic benefits. This approval is based on the results of two key clinical studies, and the single drug treatment of enoglutide injection (EECOH -1 Study) and combination of two nail and two muscle therapy (EECOH-2 Both studies have demonstrated the comprehensive benefits of enoglutide injection in lowering blood sugar, reducing body weight, and improving metabolic indicators, with sustained efficacy for 52 weeks and good overall safety and tolerability.
Novo Nordisk: GLP-1+Amylin diabetes Phase III clinical success
On February 2, 2026, Novo Nordisk announced the success of the third phase clinical REIMAGINE2 of CagriSema in the treatment of type II diabetes. 2728 patients with type 2 diabetes were enrolled in this phase III clinical study. The baseline Hb1Ac was 8.2%, and the baseline body weight was 101 kg. After 68 weeks of treatment, CagriSema, The Hb1AC of the treatment groups treated with semaglutide and placebo decreased by -1.91%, -1.76%, and+0.09%, respectively, and the body weight decreased by 14.2%, 10.2%, and 1.5%, respectively. Previously, CagriSema had achieved success in REDEFINE1 during the third phase of weight loss clinical trials.
The clinical protocol for this phase is as follows, with 3417 subjects enrolled and treated for 68 weeks. After 68 weeks of treatment with CagriSema, the weight loss was 22.7%, while the monotherapy groups with semaglutide and Cagrlintide lost 16.1% and 11.8%, respectively. The combination therapy showed a significant synergistic effect. On December 18, 2025, Novo Nordisk announced the submission of the marketing application for CagriSema to the FDA, which is also the world's first GLP-1+Amylin combination therapy.
Shengyin Biotechnology announces strategic partnership with Genentech for RNAi drug development
On February 2, 2026, Saint Yin Biotechnology, a clinical stage biotechnology company focused on innovative RNA interference (RNAi) therapy development, announced today that it has reached a global research and development cooperation and licensing agreement with Genentech (a subsidiary of Roche Group) to jointly promote the development of an RNAi therapy based on Saint Yin Biotechnology's proprietary RNAi drug development platform. According to the agreement, Shengyin Biotechnology will authorize Genentech to have exclusive global development and commercialization rights for the drug.
Shengyin Biotechnology will be responsible for the early development of the drug, while Genentech will be responsible for all subsequent clinical development and commercialization activities of the drug.
The proprietary RNAi drug development platform of Saint Yin Biotechnology covers new drug chemical modification and delivery technologies, which can be used to develop potential breakthrough SiRNA drugs for multiple disease fields. According to the terms of the agreement, Saint Yin Biotechnology will receive a down payment of $200 million and have the right to receive milestone payments for development and sales, totaling $1.5 billion; And graded royalty fees.
28 weeks reduced by 12.3%! Pfizer releases Phase Ib study data on ultra long-acting GLP-1 weight loss
On February 2, 2026, Pfizer announced the results of a weight loss Phase Ib VESPER-3 study on its ultra long-acting GLP-1R agonist PF'3944 (MET-097i). PF'3944 is a class first fully biased, ultra long acting GLP-1 receptor agonist (GLP-1 RA) developed by Metsera (now acquired by Pfizer), with the potential for monthly injection. This study included 268 obese or overweight subjects without type 2 diabetes, and evaluated the weight loss effect and safety of four titration schemes of PF'3944 compared with placebo. The titration scheme includes: ① 0.4/0.8mg, once a week (QW), 3.2mg, once a month (QM) ② 0.8 mg,Qw,3.2mg,QM0.4/0.8/1.2mg,QW,4.8mg,QMG0.6/1.2mg,QW4.8mg, QM.
The results showed that at week 28 of treatment, the weight of patients in group 1 and group 3 decreased by 10% and 12.3% respectively compared to the placebo group. These data indicate that after switching to once a month medication, the patient's weight loss remained stable, with no plateau observed at week 28. It is expected that weight loss will continue until week 64.
